Catalyst

Slingshot members are tracking this event:

Valbenazine NDA for tardive dyskinesia expected to be filed in 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NBIX Community voting in process

Additional Information

Additional Relevant Details Neurocrine has received Breakthrough Therapy Designation from the FDA for valbenazine in the treatment of tardive dyskinesia and expects to file a New Drug Application for tardive dyskinesia in 2016.
http://phoenix.corpo...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda, Tardive Dyskinesia, Valbenazine